Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 31 Issue 2
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2013  >  31(2): 81-85

ZHU Hengmei, LU Guihua, FANG Shuheng, XU Lili. Pain Management with fentanyl transdermal and morphine subcutaneous injection for the patients with advanced liver cancer pain after intervention therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 75-77. doi: 10.3969/j.issn.1006-0111.2017.01.019
Citation: LIU Yue, ZHAO Liang, LI Yan, ZHU Zhen-yu, CHAI Yi-feng. Advances in metabonomics of hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
shu

Advances in metabonomics of hepatocellular carcinoma

doi: 10.3969/j.issn.1006-0111.2013.02.001
  • 1.

    Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 2.

    Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China

  • 3.

    Zhengchangzhuang Clinic, Logistics Department of PLA, Beijing 100141, China

  • Received Date: 2012-04-16
  • Rev Recd Date: 2012-09-20
  • Hepatocellular carcinoma (HCC) was one of the most common malignancies with high incidence and mortality which threatened human health. Integrating analytical technology of high throughput and high resolution with bioinformatics, metabonomics could investigate the organism on the level of metabolism, provide a unique insight into searching biomarkers for early diagnosis of HCC and exploring the mechanism of HCC. The advances of metabonomics studies on HCC in the recent years were reviewed in this paper which could provide the reference for further research.
  • [1] Hanahan D, Weinberg R. The hallmarks of cancer[J]. Cell, 2000, 100(1):57.
    [2] World Health Organization. mortality database, WHO statistical information system.available at http://www.who.int/whosis/en/.accessed March 19, 2008.
    [3] Kassahun W, Fangmann J, Harms J, et al. Liver Resection and Transplantation in the Management of Hepatocellular Carcinoma:A Review[J]. Exp Clin Transplant, 2006, 4(2):549.
    [4] El-Serag HB, Rudolph L. Hepatocellular carcinoma:Epidemiology and molecular carcinogenesis[J]. Gastroenterology, 2007, 132(7):2557.
    [5] Anthony P. Hepatocellular carcinoma:an overview[J]. Histopathology,2001, 39(2):109.
    [6] El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States[J]. New Eng J Med, 1999, 340(10):745.
    [7] El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma[J]. Gastroenterology, 2004, 126(2):460.
    [8] El-Serag H, Mason A, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States[J]. Hepatology, 2001, 33(1):62.
    [9] Onodera H, Ukai K, Minami Y. Hepatocellular-Carcinoma Cases with 5-Year Survival and Prognostic Factors Affecting the Survival-Time[J]. Tohoku J Exp Med, 1995, 176(4):203.
    [10] Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast,and prostate cancer[J]. Science, 1997, 275(5308):1943.
    [11] Fields AC, Cotsonis G, Sexton D, et al. Survivin expression in hepatocel lular carcinoma:correlation with proliferation. prognostic parameters,and outcome[J]. Modern Pathology, 2004, 17(11):1378.
    [12] Furui J, Furukawa M, Kanematsu T. The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibody-positive patients with hepatocellular carcinoma[J]. Hepatogastroenterology,1995, 42(5):445.
    [13] Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma[J]. J Clin Gastroenterol, 2002, 35(5 Suppl. 2):S86.
    [14] Peng YC, Chan CS, Chen GH. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma[J]. Hepatogastroenterology, 1999, 46(30):3208.
    [15] Nicholson J, Lindon J, Holmes E. 'Metabonomics':understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11):1181.
    [16] Fiehn O. Metabolomics—the link between genotypes and phenotypes[J]. Plant Mol Biol,2002, 48(1-2):155.
    [17] Zhang F, Jia Z, Gao P, et al. Metabonomics study of urine and plasma in depression and excess fatigue rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry[J]. Mol BioSyst, 2010, 6(5):852.
    [18] Chen Y, Zhang R, Song Y, et al. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network:finding potential biomarkers for breast cancer[J]. Analyst, 2009, 134(10):2003.
    [19] Zhou J, Xu B, Huang J, et al. 1H NMR-based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma[J]. Clinica Chimica Acta, 2009, 401(1-2):8.
    [20] Pasikanti KK, Esuvaranathan K, Ho PC, et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer[J]. J Proteome Res, 2010, 9(6):2988.
    [21] Lindon J, Nicholson J, Holmes E. The handbook of metabonomics and metabolomics[M]. Amsterdam:elsevier BV,2007:201~226.
    [22] Schmidt C. Metabolomics takes its place as latest up-and-coming "omic" science[J]. J Natl Cancer Inst, 2004, 96(10):732.
    [23] Cao H, Huang H, Xu W, et al. Fecal metabolome pro?ling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry[J]. Analytica Chimica Acta, 2011, 691(1-2):68.
    [24] Yin P, Wan D, Zhao C, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry[J]. Mol BioSyst, 2009, 5(8):868.
    [25] Patterson AD, Maurhofer O, Beyoglu D, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling[J]. Cancer Res, 2011, 71(21):6590.
    [26] Gao H, Lu Q, Liu X, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis[J]. Cancer Sci,2009, 100(4):782.
    [27] Chen F, Xue J, Zhou L, et al. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method[J]. Anal Bioanal Chem, 2011, 401(6):1899.
    [28] Shariff MIF, Ladep NG, Cox IJ, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population[J]. J Proteome Res, 2010, 9(2):1096.
    [29] Shariff MIF, Gomaa AI, Cox IJ, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population:a validation study[J]. J Proteome Res, 2011, 10(4):1828.
    [30] Xue R, Lin Z, Deng C, et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry[J]. Rapid Commun Mass Sp, 2008, 22(19):3061.
    [31] Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma[J]. Mol Cell Proteomics, 2011, 10(7).
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0401234Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 89.4 %FULLTEXT: 89.4 %META: 8.4 %META: 8.4 %PDF: 2.2 %PDF: 2.2 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 25.8 %其他: 25.8 %China: 2.0 %China: 2.0 %[]: 0.8 %[]: 0.8 %上海: 1.2 %上海: 1.2 %中卫: 0.4 %中卫: 0.4 %临汾: 0.2 %临汾: 0.2 %丽水: 0.2 %丽水: 0.2 %亳州: 0.2 %亳州: 0.2 %信阳: 0.2 %信阳: 0.2 %兰州: 0.2 %兰州: 0.2 %北京: 17.6 %北京: 17.6 %厦门: 0.2 %厦门: 0.2 %台州: 0.2 %台州: 0.2 %合肥: 0.2 %合肥: 0.2 %呼和浩特: 0.2 %呼和浩特: 0.2 %商洛: 0.2 %商洛: 0.2 %嘉兴: 0.2 %嘉兴: 0.2 %大同: 0.2 %大同: 0.2 %大连: 0.4 %大连: 0.4 %天津: 0.4 %天津: 0.4 %太原: 0.4 %太原: 0.4 %宁波: 0.2 %宁波: 0.2 %安康: 0.2 %安康: 0.2 %宜昌: 0.2 %宜昌: 0.2 %巴音郭楞: 0.2 %巴音郭楞: 0.2 %广州: 0.2 %广州: 0.2 %廊坊: 0.2 %廊坊: 0.2 %张家口: 1.8 %张家口: 1.8 %恩施: 0.4 %恩施: 0.4 %成都: 0.6 %成都: 0.6 %昆明: 0.4 %昆明: 0.4 %昌吉: 0.2 %昌吉: 0.2 %普洱: 0.2 %普洱: 0.2 %朝阳: 0.2 %朝阳: 0.2 %杭州: 1.0 %杭州: 1.0 %武汉: 0.6 %武汉: 0.6 %沈阳: 0.2 %沈阳: 0.2 %泉州: 0.2 %泉州: 0.2 %泰州: 0.2 %泰州: 0.2 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.8 %济南: 0.8 %淄博: 0.2 %淄博: 0.2 %深圳: 0.4 %深圳: 0.4 %湖州: 0.4 %湖州: 0.4 %湛江: 0.2 %湛江: 0.2 %漳州: 0.4 %漳州: 0.4 %潍坊: 0.6 %潍坊: 0.6 %牡丹江: 0.2 %牡丹江: 0.2 %盐城: 0.4 %盐城: 0.4 %石家庄: 1.0 %石家庄: 1.0 %绍兴: 0.2 %绍兴: 0.2 %芒廷维尤: 12.4 %芒廷维尤: 12.4 %苏州: 0.6 %苏州: 0.6 %莆田: 0.4 %莆田: 0.4 %菏泽: 0.2 %菏泽: 0.2 %衢州: 0.2 %衢州: 0.2 %西宁: 15.2 %西宁: 15.2 %西安: 0.4 %西安: 0.4 %贵阳: 0.2 %贵阳: 0.2 %运城: 0.4 %运城: 0.4 %重庆: 0.6 %重庆: 0.6 %铁岭: 0.2 %铁岭: 0.2 %铜川: 0.2 %铜川: 0.2 %银川: 0.2 %银川: 0.2 %镇江: 0.2 %镇江: 0.2 %长春: 0.4 %长春: 0.4 %长沙: 1.4 %长沙: 1.4 %长治: 0.4 %长治: 0.4 %阜新: 0.2 %阜新: 0.2 %青岛: 1.0 %青岛: 1.0 %鞍山: 0.2 %鞍山: 0.2 %驻马店: 0.2 %驻马店: 0.2 %黄冈: 1.0 %黄冈: 1.0 %其他China[]上海中卫临汾丽水亳州信阳兰州北京厦门台州合肥呼和浩特商洛嘉兴大同大连天津太原宁波安康宜昌巴音郭楞广州廊坊张家口恩施成都昆明昌吉普洱朝阳杭州武汉沈阳泉州泰州洛阳济南淄博深圳湖州湛江漳州潍坊牡丹江盐城石家庄绍兴芒廷维尤苏州莆田菏泽衢州西宁西安贵阳运城重庆铁岭铜川银川镇江长春长沙长治阜新青岛鞍山驻马店黄冈Highcharts.com

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4157) PDF downloads(143) Cited by(1)

Related
Proportional views

Advances in metabonomics of hepatocellular carcinoma

doi: 10.3969/j.issn.1006-0111.2013.02.001
  • 1. Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
  • 2. Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
  • 3. Zhengchangzhuang Clinic, Logistics Department of PLA, Beijing 100141, China
  • Received Date: 2012-04-16
  • Rev Recd Date: 2012-09-20

Abstract: Hepatocellular carcinoma (HCC) was one of the most common malignancies with high incidence and mortality which threatened human health. Integrating analytical technology of high throughput and high resolution with bioinformatics, metabonomics could investigate the organism on the level of metabolism, provide a unique insight into searching biomarkers for early diagnosis of HCC and exploring the mechanism of HCC. The advances of metabonomics studies on HCC in the recent years were reviewed in this paper which could provide the reference for further research.

ZHU Hengmei, LU Guihua, FANG Shuheng, XU Lili. Pain Management with fentanyl transdermal and morphine subcutaneous injection for the patients with advanced liver cancer pain after intervention therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 75-77. doi: 10.3969/j.issn.1006-0111.2017.01.019
Citation: LIU Yue, ZHAO Liang, LI Yan, ZHU Zhen-yu, CHAI Yi-feng. Advances in metabonomics of hepatocellular carcinoma[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(2): 81-85. doi: 10.3969/j.issn.1006-0111.2013.02.001
shu

    HTML

Reference (31)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return